| [1] |
Quan ML, Paszat LF, Fernandes KA, et al. The effect of surgery type on survival and recurrence in very young women with breast cancer[J]. J Surg Oncol, 2017, 115(2): 122-130.
|
| [2] |
van Maaren MC, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study[J]. Lancet Oncol, 2016, 17(8): 1158-1170.
|
| [3] |
Kiess AP, McArthur HL, Mahoney K, et al. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer[J]. Cancer，2012, 118(8): 1982-1988.
|
| [4] |
Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer[J]. Br J Surg, 2007, 94(10): 1189-1200.
|
| [5] |
Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy[J]. Cancer, 2005, 103(4): 689-695.
|
| [6] |
Rouzier R, Extra JM, Carton M, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery[J]. J Clin Oncol，2001, 19(18): 3828-3835.
|
| [7] |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26(16): 2793.
|
| [8] |
Criscitiello C, Azim HA Jr, Agbor-Tarh D, et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase Ⅲ trial[J]. Ann Oncol, 2013, 24(8): 1980-1985.
|
| [9] |
江泽飞，李健斌. 精准医学时代乳腺外科十个热点问题思考[J/CD]. 中华普外科手术学杂志(电子版), 2016, 10(3): 192-196.
|
| [10] |
Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer[J]. Ann Surg, 2006, 244(3): 464-470.
|
| [11] |
杨涛，王永胜. 乳腺癌新辅助化疗后局部区域外科处理进展[J]. 中国普外基础与临床杂志, 2014, 21(5): 583-588.
|
| [12] |
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial[J]. JAMA, 2011, 305(6): 569-575.
|
| [13] |
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2013, 14(4): 297-305.
|
| [14] |
Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel lymph node resection and conventional axillary lymph node dissection in patients with clinically node-negative breast cancer[J]. Lancet Oncol, 2007, 8(10): 881-888.
|
| [15] |
Kelly AM, Dwamena B, Cronin P, et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy: systematic review and meta-analysis[J]. Acad Radiol, 2009, 16(5): 551-563.
|
| [16] |
van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review[J]. Eur J Cancer, 2009, 45(18): 3124-3130.
|
| [17] |
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA, 2013, 310(14): 1455-1461.
|
| [18] |
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvantchemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
|
| [19] |
尉承泽. 乳腺癌前哨淋巴结活检现状及值得注意的问题[J]. 中国实用外科杂志, 2011, 31(10): 955-958.
|
| [20] |
赵晶，尉承泽. 乳腺癌新辅助化疗前后前哨淋巴结活检的应用现状[J]. 临床误诊误治, 2012, 25(9): 94-97.
|
| [21] |
于跃，贾淞淋，盛湲. 乳腺癌患者新辅助化疗后行前哨淋巴结活检可行性的系统评价[J]. 第二军医大学学报, 2016, 31(1): 120-126.
|